Developing therapies for peanut allergy

International Archives of Allergy and Immunology

Volumn 165, Issue 3, 2014, Pages 179-194

  Bublin, Merima ^a   Breiteneder, Heimo ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergen nonspecific immunotherapy; Allergen specific immunotherapy; Ara h 2; Oral immunotherapy; Peanut allergy

Indexed keywords

ADJUVANT; DAIDZEIN; GENISTEIN; OMALIZUMAB; PEANUT EXTRACT; PLACEBO; PLASMID DNA; TALIZUMAB; TOLL LIKE RECEPTOR 9; ALLERGEN; PLANT ANTIGEN;

CROSSOVER PROCEDURE; FOOD ALLERGY; GENETIC IMMUNIZATION; HUMAN; IMMUNOTHERAPY; INTESTINE EPITHELIUM; LACTIC ACID BACTERIUM; NON INVASIVE PROCEDURE; PEANUT ALLERGY; PRIORITY JOURNAL; REVIEW; SOYBEAN; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TRANSGENIC PLANT; ADVERSE EFFECTS; ANIMAL; ARACHIS; DESENSITIZATION; IMMUNOLOGY; PEANUT HYPERSENSITIVITY; PROCEDURES; TRENDS;

ALLERGENS; ANIMALS; ANTIGENS, PLANT; ARACHIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PEANUT HYPERSENSITIVITY;

EID: 84920018443     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000369340     Document Type: Review

References (131)

1. Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA: The natural history of peanut allergy. J Allergy Clin Immunol 2001; 107: 367-374.
2. Osborne NJ, Koplin JJ, Martin PE, Gurrin LC, Lowe AJ, Matheson MC, Ponsonby AL, Wake M, Tang ML, Dharmage SC, Allen KJ: Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol 2011; 127: 668-676.
3. Soller L, Ben-Shoshan M, Harrington DW, Fragapane J, Joseph L, St Pierre Y, Godefroy SB, La Vieille S, Elliott SJ, Clarke AE: Overall prevalence of self-reported food allergy in Canada. J Allergy Clin Immunol 2012; 130: 986-988.
4. Nicolaou N, Poorafshar M, Murray C, Simpson A, Winell H, Kerry G, Harlin A, Woodcock A, Ahlstedt S, Custovic A: Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol 2010; 125: 191-197.
5. Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, Kamilaris J, Burks AW: Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol 2009; 124: 286-291.
6. Pumphrey R: Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4: 285-290.
7. Greenhawt M, MacGillivray F, Batty G, Said M, Weiss C: International study of risk-mitigating factors and in-flight allergic reactions to peanut and tree nut. J Allergy Clin Immunol Pract 2013; 1: 186-194.
8. Flokstra-de Blok BM, van der Velde JL, Vlieg-Boerstra BJ, Oude Elberink JN, DunnGalvin A, Hourihane JO, Duiverman EJ, Dubois AE: Health-related quality of life of food-Allergic patients measured with generic and disease-specific questionnaires. Allergy 2010; 65: 1031-1038.
9. Jones SM, Burks AW, Dupont C: State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J Allergy Clin Immunol 2014; 133: 318-323.
10. Erekosima N, Suarez-Cuervo C, Ramanathan M, Kim JM, Chelladurai Y, Segal JB, Lin SY: Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014; 124: 616-627.
11. Frew AJ, Powell RJ, Corrigan CJ, Durham SR: Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 319-325.
12. Lent AM, Harbeck R, Strand M, Sills M, Schmidt K, Efaw B, Lebo T, Nelson HS: Immunologic response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 2006; 118: 1249-1256.
13. Roberts G, Hurley C, Turcanu V, Lack G: Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117: 263-268.
14. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY: Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol 1992; 90: 256-262.
15. Nelson HS, Lahr J, Rule R, Bock A, Leung D: Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997; 99: 744-751.
16. Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, Hiegel A, Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks AW: A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011; 127: 654-660.
17. Anagnostou K, Clark A, King Y, Islam S, Deighton J, Ewan P: Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy 2011; 41: 1273-1281.
18. Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, Palmer C, Deighton J, Ewan P, Clark A: Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014; 383: 1297-1304.
19. Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Oliveira LC, Shreffler WG, Sampson HA, Niggemann B, Wahn U, Beyer K: Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol 2010; 126: 83-91.
20. Clark AT, Islam S, King Y, Deighton J, Anagnostou K, Ewan PW: Successful oral tolerance induction in severe peanut allergy. Allergy 2009; 64: 1218-1220.
21. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler WG, Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X, Burks AW: Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009; 124: 292-300.
22. Varshney P, Jones SM, Pons L, Kulis M, Steele PH, Kemper AR, Scurlock AM, Perry TT, Burks AW: Oral immunotherapy (OIT) induces clinical tolerance in peanut-Allergic children. J Allergy Clin Immunol 2009; 123:S174.
23. Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW: Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol 2014; 133: 468-475.
24. Vickery BP, Lin J, Kulis M, Fu Z, Steele PH, Jones SM, Scurlock AM, Gimenez G, Bardina L, Sampson HA, Burks AW: Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. J Allergy Clin Immunol 2013; 131: 128-134.
25. Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, Berglund JP, Tsai M, Maecker H, O'Riordan G, Galli SJ, Nadeau KC: Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol 2014; 133: 500-510.
26. Nurmatov U, Devereux G, Worth A, Healy L, Sheikh A: Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-Analysis. Br J Nutr 2014; 111: 12-22.
27. Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A: Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst Rev 2012; 9:CD009014.
28. Sheikh A, Nurmatov U, Venderbosch I, Bischoff E: Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies. Prim Care Respir J 2012; 21: 41-49.
29. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, Bousquet J, Calderon M, Compalati E, Durham SR, van Wijk RG, Larenas-Linnemann D, Nelson H, Passalacqua G, Pfaar O, Rosario N, Ryan D, Rosenwasser L, Schmid-Grendelmeier P, Senna G, Valovirta E, Van Bever H, Vichyanond P, Wahn U, Yusuf O: Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014; 7: 6.
30. Novak N, Bieber T, Allam JP: Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy 2011; 66: 733-739.
31. Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, Steele P, Kamilaris J, Vickery B, Burks AW: Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011; 127: 640-646.
32. Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, Sicherer SH, Liu AH, Stablein D, Henning AK, Mayer L, Lindblad R, Plaut M, Sampson HA: Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013; 131: 119-127.
33. Chin SJ, Vickery BP, Kulis MD, Kim EH, Varshney P, Steele P, Kamilaris J, Hiegel AM, Carlisle SK, Smith PB, Scurlock AM, Jones SM, Burks AW: Sublingual versus oral immunotherapy for peanut-Allergic children: a retrospective comparison. J Allergy Clin Immunol 2013; 132: 476-478.
34. Kulis M, Saba K, Kim EH, Bird JA, Kamilaris N, Vickery BP, Staats H, Burks AW: Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy. J Allergy Clin Immunol 2012; 129: 1159-1162.
35. Yancey AL, Kulis MD, Steele PH, Kim E, Vickery BP, Burks AW: Increases in peanutspecific IgA1 and IgA2 during peanut immunotherapy do not correlate with clinical tolerance. J Allergy Clin Immunol 2014; 133: Ab104.
36. Soury D, Barratt G, Ah-Leung S, Legrand P, Chacun H, Ponchel G: Skin localization of cow's milk proteins delivered by a new readyto-use atopy patch test. Pharm Res 2005; 22: 1530-1536.
37. Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Benhamou PH, Dupont C: Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol 2011; 186: 5629-5637.
38. Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Dupont C, Benhamou PH: Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 2010; 40: 659-667.
39. Mondoulet L, Dioszeghy V, Vanoirbeek JA, Nemery B, Dupont C, Benhamou PH: Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol 2010; 154: 299-309.
40. Mondoulet L, Dioszeghy V, Larcher T, Ligouis M, Dhelft V, Puteaux E, Cherel Y, Letourneur F, Dupont C, Benhamou PH: Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One 2012; 7: e31967.
41. Dupont C, Bourrier T, de Blay F, Guenard-Bilbault L, Sauvage C, Cousin MO, Kanny G, Jarlot S, Karila C: Peanut Epicutaneous Immunotherapy (EPIT) in peanut-Allergic children: months treatment in the Arachild study. J Allergy Clin Immunol 2014; 133: Ab102.
42. Agbotounou W, Martin L, Dupont B, Pascal I, Vauleon C, Benhamou P: Epicutaneous immunotherapy for treating peanut allergy: results of the first double-blind, placebocontrolled safety study. Allergy 2012; 67: 33-34.
43. Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Dupont C, Benhamou PH: The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut sensitized mice. Clin Exp Allergy 2014; 44: 867-881.
44. Burks AW, Shin D, Cockrell G, Stanley JS, Helm RM, Bannon GA: Mapping and mutational analysis of the IgE-binding epitopes on Ara h 1, a legume vicilin protein and a major allergen in peanut hypersensitivity. Eur J Biochem 1997; 245: 334-339.
45. King N, Helm R, Stanley JS, Vieths S, Luttkopf D, Hatahet L, Sampson H, Pons L, Burks W, Bannon GA: Allergenic characteristics of a modified peanut allergen. Mol Nutr Food Res 2005; 49: 963-971.
46. Stanley JS, King N, Burks AW, Huang SK, Sampson H, Cockrell G, Helm RM, West CM, Bannon GA: Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Arch Biochem Biophys 1997; 342: 244-253.
47. Rabjohn P, Helm EM, Stanley JS, West CM, Sampson HA, Burks AW, Bannon GA: Molecular cloning and epitope analysis of the peanut allergen Ara h 3. J Clin Invest 1999; 103: 535-542.
48. Bannon GA, Cockrell G, Connaughton C, West CM, Helm R, Stanley JS, King N, Rabjohn P, Sampson HA, Burks AW: Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 2001; 124: 70-72.
49. Yeung VP, Gieni RS, Umetsu DT, DeKruyff RH: Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol 1998; 161: 4146-4152.
50. Li XM, Srivastava K, Huleatt JW, Bottomly K, Burks AW, Sampson HA: Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol 2003; 170: 3289-3295.
51. Li XM, Srivastava K, Grishin A, Huang CK, Schofield B, Burks W, Sampson HA: Persistent protective effect of heat-killed Escherichia coli producing 'engineered,' recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 2003; 112: 159-167.
52. Wood RA, Sicherer SH, Burks AW, Grishin A, Henning AK, Lindblad R, Stablein D, Sampson HA: A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy 2013; 68: 803-808.
53. Lin J, Bruni FM, Fu ZY, Maloney J, Bardina L, Boner AL, Gimenez G, Sampson HA: A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay. J Allergy Clin Immunol 2012; 129: 1321-1328.
54. Nicolaou N, Murray C, Belgrave D, Poorafshar M, Simpson A, Custovic A: Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. J Allergy Clin Immunol 2011; 127: 684-685.
55. Chen XN, Wang Q, El-Mezayen R, Zhuang YH, Dreskin SC: Ara h 2 and Ara h 6 have similar allergenic activity and are substantially redundant. Int Arch Allergy Immunol 2013; 160: 251-258.
56. Porterfield HS, Murray KS, Schlichting DG, Chen X, Hansen KC, Duncan MW, Dreskin SC: Effector activity of peanut allergens: a critical role for Ara h 2, Ara h 6, and their variants. Clin Exp Allergy 2009; 39: 1099-1108.
57. Asarnoj A, Moverare R, Ostblom E, Poorafshar M, Lilja G, Hedlin G, van Hage M, Ahlstedt S, Wickman M: IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds. Allergy 2010; 65: 1189-1195.
58. Astier C, Morisset M, Roitel O, Codreanu F, Jacquenet S, Franck P, Ogier V, Petit N, Proust B, Moneret-Vautrin DA, Burks AW, Bihain B, Sampson HA, Kanny G: Predictive value of skin prick tests using recombinant allergens for diagnosis of peanut allergy. J Allergy Clin Immunol 2006; 118: 250-256.
59. Flinterman AE, Knol EF, Lencer DA, Bardina L, den Hartog Jager CF, Lin J, Pasmans SG, Bruijnzeel-Koomen CA, Sampson HA, van Hoffen E, Shreffler WG: Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. J Allergy Clin Immunol 2008; 121: 737-743.
60. Peeters KA, Koppelman SJ, van Hoffen E, van der Tas CW, den Hartog Jager CF, Penninks AH, Hefle SL, Bruijnzeel-Koomen CA, Knol EF, Knulst AC: Does skin prick test reactivity to purified allergens correlate with clinical severity of peanut allergy? Clin Exp Allergy 2007; 37: 108-115.
61. Bublin M, Kostadinova M, Radauer C, Hafner C, Szepfalusi Z, Varga EM, Maleki SJ, Hoffmann-Sommergruber K, Breiteneder H: IgE cross-reactivity between the major peanut allergen Ara h 2 and the nonhomologous allergens Ara h 1 and Ara h 3. J Allergy Clin Immunol 2013; 132: 118-124.
62. Schabussova I, Wiedermann U: Lactic acid bacteria as novel adjuvant systems for prevention and treatment of atopic diseases. Curr Opin Allergy Clin Immunol 2008; 8: 557-564.
63. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M: Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2007; 119: 192-198.
64. Marschan E, Kuitunen M, Kukkonen K, Poussa T, Sarnesto A, Haahtela T, Korpela R, Savilahti E, Vaarala O: Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 2008; 38: 611-618.
65. Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J, Kraft D, Breiteneder H, Mercenier A, Wiedermann U: Mucosal co-Application of lactic acid bacteria and allergen induces counterregulatory immune responses in a murine model of birch pollen allergy. Vaccine 2003; 22: 87-95.
66. Hisbergues M, Magi M, Rigaux P, Steuve J, Garcia L, Goudercourt D, Pot B, Pestel J, Jacquet A: In vivo and in vitro immunomodulation of Der p 1 allergen-specific response by Lactobacillus plantarum bacteria. Clin Exp Allergy 2007; 37: 1286-1295.
67. Bjorksten B: Effects of intestinal microflora and the environment on the development of asthma and allergy. Springer Semin Immunopathol 2004; 25: 257-270.
68. Wells JM, Mercenier A: Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008; 6: 349-362.
69. de Jonge JD, Ezendam J, Knippels LM, Penninks AH, Pieters R, van Loveren H: Lactobacillus casei Shirota does not decrease the food allergic response to peanut extract in brown Norway rats. Toxicology 2008; 249: 140-145.
70. Zhang T, Pan W, Takebe M, Schofield B, Sampson H, Li XM: Therapeutic effects of a fermented soy product on peanut hypersensitivity is associated with modulation of Thelper type 1 and T-helper type 2 responses. Clin Exp Allergy 2008; 38: 1808-1818.
71. Masilamani M, Wei J, Sampson HA: Regulation of the immune response by soybean isoflavones. Immunol Res 2012; 54: 95-110.
72. Masilamani M, Wei J, Bhatt S, Paul M, Yakir S, Sampson HA: Soybean isoflavones regulate dendritic cell function and suppress allergic sensitization to peanut. J Allergy Clin Immunol 2011; 128: 1242-1250.
73. Wei J, Bhatt S, Chang LM, Sampson HA, Masilamani M: Isoflavones, genistein and daidzein, regulate mucosal immune response by suppressing dendritic cell function. PLoS One 2012; 7:e47979.
74. Larche M: T cell epitope-based allergy vaccines. Curr Top Microbiol Immunol 2011; 352: 107-119.
75. Yang M, Yang C, Mine Y: Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3-And transforming growth factor-beta-Associated mechanisms. Clin Exp Allergy 2010; 40: 668-678.
76. Rupa P, Mine Y: Oral immunotherapy with immunodominant T-cell epitope peptides alleviates allergic reactions in a Balb/c mouse model of egg allergy. Allergy 2012; 67: 74-82.
77. Glaspole IN, de Leon MP, Rolland JM, O'Hehir RE: Characterization of the T-cell epitopes of a major peanut allergen, Ara h 2. Allergy 2005; 60: 35-40.
78. Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE: Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol 2011; 127: 608-615.
79. DeLong JH, Simpson KH, Wambre E, James EA, Robinson D, Kwok WW: Ara h 1-reactive T cells in individuals with peanut allergy. J Allergy Clin Immunol 2011; 127: 1211-1218.
80. Prickett SR, Voskamp AL, Phan T, Dacumos-Hill A, Mannering SI, Rolland JM, O'Hehir RE: Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clin Exp Allergy 2013; 43: 684-697.
81. Sicherer SH, Sampson HA: Peanut allergy: emerging concepts and approaches for an apparent epidemic. J Allergy Clin Immunol 2007; 120: 491-503.
82. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL: Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
83. Tang DC, DeVit M, Johnston SA: Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-154.
84. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-1749.
85. Weiss R, Scheiblhofer S, Gabler M, Ferreira F, Leitner WW, Thalhamer J: Is genetic vaccination against allergy possible? Int Arch Allergy Immunol 2006; 139: 332-345.
86. Roy K, Mao HQ, Huang SK, Leong KW: Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-391.
87. Li X, Huang CK, Schofield BH, Burks AW, Bannon GA, Kim KH, Huang SK, Sampson HA: Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J Immunol 1999; 162: 3045-3052.
88. Chatel JM, Song L, Bhogal B, Orson FM: Various factors (allergen nature, mouse strain, CpG/recombinant protein expressed) influence the immune response elicited by genetic immunization. Allergy 2003; 58: 641-647.
89. Weiner L, Heiland T, Mackler B, Fitzpatrick D, Hearl B, Anagnostou A: Phase I study of Jrc-Lamp-Vax, a DNA immunotherapy vaccine to treat Japanese Red Cedar allergy. Ann Allergy Asthma Immunol 2013; 111: A8-A9.
90. Fu D, Uauy C, Blechl A, Dubcovsky J: RNA interference for wheat functional gene analysis. Transgenic Res 2007; 16: 689-701.
91. Nakamura R, Matsuda T: Rice allergenic protein and molecular-genetic approach for hypoallergenic rice. Biosci Biotechnol Biochem 1996; 60: 1215-1221.
92. Herman EM, Helm RM, Jung R, Kinney AJ: Genetic modification removes an immunodominant allergen from soybean. Plant Physiol 2003; 132: 36-43.
93. Gilissen LJ, Bolhaar ST, Matos CI, Rouwendal GJ, Boone MJ, Krens FA, Zuidmeer L, Van Leeuwen A, Akkerdaas J, Hoffmann-Sommergruber K, Knulst AC, Bosch D, Van de Weg WE, Van Ree R: Silencing the major apple allergen Mal d 1 by using the RNA interference approach. J Allergy Clin Immunol 2005; 115: 364-369.
94. Le LQ, Mahler V, Lorenz Y, Scheurer S, Biemelt S, Vieths S, Sonnewald U: Reduced allergenicity of tomato fruits harvested from Lyc e 1-silenced transgenic tomato plants. J Allergy Clin Immunol 2006; 118: 1176-1183.
95. Lorenz Y, Enrique E, Lequynh L, Fotisch K, Retzek M, Biemelt S, Sonnewald U, Vieths S, Scheurer S: Skin prick tests reveal stable and heritable reduction of allergenic potency of gene-silenced tomato fruits. J Allergy Clin Immunol 2006; 118: 711-718.
96. Dodo HW, Konan KN, Chen FC, Egnin M, Viquez OM: Alleviating peanut allergy using genetic engineering: the silencing of the immunodominant allergen Ara h 2 leads to its significant reduction and a decrease in peanut allergenicity. Plant Biotechnol J 2008; 6: 135-145.
97. Burks AW: Peanut allergy. Lancet 2008; 371: 1538-1546.
98. Chu Y, Faustinelli P, Ramos ML, Hajduch M, Stevenson S, Thelen JJ, Maleki SJ, Cheng H, Ozias-Akins P: Reduction of IgE binding and nonpromotion of Aspergillus flavus fungal growth by simultaneously silencing Ara h 2 and Ara h 6 in peanut. J Agric Food Chem 2008; 56: 11225-11233.
99. Krause S, Latendorf T, Schmidt H, Darcan-Nicolaisen Y, Reese G, Petersen A, Janssen O, Becker WM: Peanut varieties with reduced Ara h 1 content indicating no reduced allergenicity. Mol Nutr Food Res 2010; 54: 381-387.
100. Chang TW: The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000; 18: 157-162.
101. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-190.
102. Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, Fowler-Taylor A, Liu J, Gupta N: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111: 278-284.
103. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD: Efficacy and safety of a recombinant antiimmunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632-638.
104. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD: The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302-308.
105. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, Shen H, Fox H: Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 160-167.
106. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Grave M, Hultsch T, Wahn U: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 274-280.
107. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U: Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39: 271-279.
108. Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W, Kilchherr E, Staehelin T, Davis F, Gordon W, Sun L, Liou R, Wang G, Chang TW, Holgate S: The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997; 99: 879-887.
109. Gomez G, Jogie-Brahim S, Shima M, Schwartz LB: Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells. J Immunol 2007; 179: 1353-1361.
110. Noga O, Hanf G, Kunkel G, Kleine-Tebbe J: Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol 2008; 146: 66-70.
111. Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, Wong DA: A phase II, randomized, double-blind, parallelgroup, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127: 1309-1310.
112. Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR Jr: Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348: 986-993.
113. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT: A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-Allergic patients. J Allergy Clin Immunol 2013; 132: 1368-1374.
114. Lee SY, Huang CK, Zhang TF, Schofield BH, Burks AW, Bannon GA, Sampson HA, Li XM: Oral administration of IL-12 suppresses anaphylactic reactions in a murine model of peanut hypersensitivity. Clin Immunol 2001; 101: 220-228.
115. Kishida T, Hiromura Y, Shin-Ya M, Asada H, Kuriyama H, Sugai M, Shimizu A, Yokota Y, Hama T, Imanishi J, Hisa Y, Mazda O: IL-21 induces inhibitor of differentiation and leads to complete abrogation of anaphylaxis in mice. J Immunol 2007; 179: 8554-8561.
116. Liu Y, Sun Y, Chang LJ, Li N, Li H, Yu Y, Bryce PJ, Grammer LC, Schleimer RP, Zhu D: Blockade of peanut allergy with a novel Ara h 2-Fcgamma fusion protein in mice. J Allergy Clin Immunol 2013; 131: 213-221.
117. Li XM, Brown L: Efficacy and mechanisms of action of traditional Chinese medicines for treating asthma and allergy. J Allergy Clin Immunol 2009; 123: 297-306; quiz 7-8.
118. Li XM: Complementary and alternative medicine in pediatric allergic disorders. Curr Opin Allergy Clin Immunol 2009; 9: 161-167.
119. Li XM, Zhang TF, Huang CK, Srivastava K, Teper AA, Zhang L, Schofield BH, Sampson HA: Food Allergy Herbal Formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J Allergy Clin Immunol 2001; 108: 639-646.
120. Srivastava KD, Qu C, Zhang T, Goldfarb J, Sampson HA, Li XM: Food Allergy Herbal Formula-2 silences peanut-induced anaphylaxis for a prolonged posttreatment period via IFN-gamma-producing CD8+ T cells. J Allergy Clin Immunol 2009; 123: 443-451.
121. Srivastava KD, Kattan JD, Zou ZM, Li JH, Zhang L, Wallenstein S, Goldfarb J, Sampson HA, Li XM: The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J Allergy Clin Immunol 2005; 115: 171-178.
122. Qu C, Srivastava K, Ko J, Zhang TF, Sampson HA, Li XM: Induction of tolerance after establishment of peanut allergy by the Food Allergy Herbal Formula-2 is associated with up-regulation of interferon-gamma. Clin Exp Allergy 2007; 37: 846-855.
123. Patil SP, Wang J, Song Y, Noone S, Yang N, Wallenstein S, Sampson HA, Li XM: Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: extended phase I study. J Allergy Clin Immunol 2011; 128: 1259-1265.
124. Wang J, Patil SP, Yang N, Ko J, Lee J, Noone S, Sampson HA, Li XM: Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol 2010; 105: 75-84.
125. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-484.
126. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D: Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355: 1445-1455.
127. Berin MC, Wang W: Reduced severity of peanut-induced anaphylaxis in TLR9-deficient mice is associated with selective defects in humoral immunity. Mucosal Immunol 2013; 6: 114-121.
128. Pochard P, Vickery B, Berin MC, Grishin A, Sampson HA, Caplan M, Bottomly K: Targeting Toll-like receptors on dendritic cells modifies the T(H)2 response to peanut allergens in vitro. J Allergy Clin Immunol 2010; 126: 92-97.
129. Kulis M, Gorentla B, Burks AW, Zhong XP: Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice. Mol Nutr Food Res 2013; 57: 906-915.
130. Zhu FG, Kandimalla ER, Yu D, Agrawal S: Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. J Allergy Clin Immunol 2007; 120: 631-637.
131. Adel-Patient K, Ah-Leung S, Bernard H, Durieux-Alexandrenne C, Creminon C, Wal JM: Oral sensitization to peanut is highly enhanced by application of peanut extracts to intact skin, but is prevented when CpG and cholera toxin are added. Int Arch Allergy Immunol 2007; 143: 10-20.